NCT07714057

Brief Summary

The goal of this clinical trial is to evaluate whether hydrogen-rich water supplementation during tapering improves recovery after functional overreaching in competitive male basketball players aged 18-35 years. The main questions it aims to answer are:

  • Does hydrogen-rich water improve autonomic recovery after functional overreaching?
  • Does hydrogen-rich water improve recovery in biochemical, performance, and subjective feeling outcomes during tapering? Researchers will compare hydrogen-rich water to placebo (water containing no molecular hydrogen) to determine whether molecular hydrogen improves recovery after accumulated fatigue has been induced by functional overreaching. Participants will:
  • Complete a training cycle including normal training, functional overreaching, and tapering.
  • Consume hydrogen-rich or placebo water daily during the one-week tapering period.
  • Undergo repeated testing of autonomic nervous system, blood biochemical markers, performance, and subjective soreness.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
4mo left

Started Jul 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress7%
Jul 2026Dec 2026

First Submitted

Initial submission to the registry

July 15, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 20, 2026

Completed
7 days until next milestone

Study Start

First participant enrolled

July 27, 2026

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

July 28, 2026

Status Verified

July 1, 2026

Enrollment Period

4 months

First QC Date

July 15, 2026

Last Update Submit

July 27, 2026

Conditions

Healthy Active Athletes

Keywords

molecular hydrogenfunctional overreachingtaperingheart rate variabilitybasketball

Outcome Measures

Primary Outcomes (1)

  • RMSSD

    The root mean square of successive differences of RR intervals (RMSSD) is used as an index of parasympathetic activity and is calculated from an ECG using heart rate variability analysis.

    One-week change between post-overreaching and post-taper.

Secondary Outcomes (15)

  • Creatine kinase

    One-week change between post-overreaching and post-taper.

  • High-sensitivity C-reactive protein

    One-week change between post-overreaching and post-taper.

  • Cortisol

    One-week change between post-overreaching and post-taper.

  • Testosterone

    One-week change between post-overreaching and post-taper.

  • Urea

    One-week change between post-overreaching and post-taper.

  • +10 more secondary outcomes

Study Arms (2)

Hydrogen-rich water

EXPERIMENTAL

Hydrogen-rich water administered at a dose of 2.5 L per day during a one-week tapering period.

Dietary Supplement: Hydrogen-rich water

Placebo water

PLACEBO COMPARATOR

Placebo water administered at a dose of 2.5 L per day during a one-week tapering period.

Dietary Supplement: Placebo water

Interventions

Hydrogen-rich waterDIETARY_SUPPLEMENT

Hydrogen-rich water with molecular hydrogen concentration \>1.0 ppm.

Also known as: Tirtan generator (Nutristamina, Ostrava, Czech Republic)
Hydrogen-rich water
Placebo waterDIETARY_SUPPLEMENT

Tap water without molecular hydrogen.

Placebo water

Eligibility Criteria

Age18 Years - 35 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsCisgender men.
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Competitive male basketball players.
  • Signed informed consent.
  • Completion of entry medical and laboratory screening.

You may not qualify if:

  • Acute injury or infection.
  • History or presence of relevant cardiovascular, respiratory, metabolic, or other disease that may affect the study results.
  • Use of medication affecting recovery markers or study results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Palacky University, Faculty of Physical Culture

Olomouc, 77111, Czechia

RECRUITING

Study Officials

  • Jan Kvas

    Palacky University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jan Kvas

CONTACT

+420774678756jan.kvas01@upol.cz

Jakub Krejci, PhD

CONTACT

jakub.krejci@upol.cz

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

July 15, 2026

First Posted

July 20, 2026

Study Start

July 27, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

July 28, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will share

All IPD that underlie results in a publication.

Time Frame
Beginning 1 month after the publication of results with no end date.
Access Criteria
Anonymized IPD will be uploaded to an open-access data repository.

Locations

CZ(1)